Its expression level was significantly in positive correlation with the poor overall survival of patients with BC or hepatocellular carcinoma (HCC) and with the potential adverse effect of patients to PD-1 antibody therapy [12,13,14,15]. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.